Posted by Michael Wonder on 24 Jul 2024
AbbVie's Epkinly receives first ever time-limited reimbursement recommendation by Canada's Drug Agency
23 July 2024 - AbbVie has successfully completed its negotiations with the pan-Canadian Pharmaceutical Alliance and a letter of intent has been signed by both parties.
AbbVie today announced that Canada's Drug Agency (CDA, formerly CADTH) has issued its first-ever time-limited reimbursement recommendation for Epkinly (epcoritamab).
